Drug Profile
Doxorubicin peptide conjugate - Watson
Latest Information Update: 10 Apr 2008
Price :
$50
*
At a glance
- Originator Watson Laboratories
- Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 16 Jan 2001 TheraTech is now called Watson Laboratories
- 04 May 1999 Preclinical development for Rheumatoid arthritis in USA (Unknown route)